PARP Inhibitor Biomarkers Market Size & Share 2026-2035

PARP Inhibitor Biomarkers Market Size

The PARP inhibitor biomarkers market was valued at USD 1 billion in 2025 and is projected to reach USD 2.4 billion by 2035, expanding at a CAGR of 8.7%, according to GMI estimates. Biomarker testing sits at the treatment-selection point for PARP inhibitors: it identifies BRCA alterations and broader homologous recombination deficiency (HRD) patterns that can determine whether a patient is considered for a targeted regimen.

Clinical demand begins with cancer burden but is shaped by the prevalence of actionable biology. Breast cancer caused about 670,000 deaths worldwide in 2022 and was the most commonly diagnosed cancer among women in 157 of 185 countries.^{[1]WHO/IARC, Global cancer burden growing amid mounting need for services. who.int} In unselected breast cancer, BRCA1/2 pathogenic variants occur in roughly 2–3% of cases, with higher prevalence in early-onset disease; the corresponding estimate in ovarian cancer is 10–15%.^{[2]National Cancer Institute, BRCA1 and BRCA2: Cancer Risks and Management (PDQ). cancer.gov} HRD broadens the testing question beyond BRCA mutations, particularly in high-grade serous ovarian cancer and triple-negative breast cancer, where published estimates show substantial prevalence.

Technology is changing the economics and clinical utility of testing rather than simply increasing laboratory throughput. The estimated cost of sequencing a human genome fell from about USD 95 million in 2001 to approximately USD 500 in 2022. Lower sequencing costs enable broader panels and iterative re-testing, while bioinformatics determines whether a laboratory can convert multi-gene data into a report usable for therapy selection. The resulting value proposition is strongest when a test avoids an ineffective high-cost therapy or identifies a patient with a clinically actionable alteration. OECD analysis estimated cancer costs to health systems at EUR PPP 449 billion and projected a 67% increase in per-capita costs by 2050, reinforcing payer interest in evidence-based treatment selection.

The market's cost pressure is two-sided. Falling sequencing costs improve the feasibility of comprehensive testing, yet oncology budgets remain constrained by rising treatment expenditures. Laboratories and test developers therefore need to demonstrate that broader profiling changes prescribing decisions, not merely that it detects more variants. Platforms that shorten the path from specimen to treatment recommendation are better positioned than those that add analytical complexity without resolving clinical uncertainty.

The market covers products and services used to identify BRCA1/2 mutations, HRD, and related homologous recombination repair alterations that inform PARP inhibitor treatment decisions across oncology settings.

Key Drivers

Increasing prevalence of breast cancer. The breast cancer burden sustains the testing funnel for hereditary-risk and treatment-selection diagnostics. PARP inhibitors are approved in BRCA-mutated, HER2-negative breast cancer, making molecular confirmation integral to identifying eligible patients.^{[3]Baretta et al., HRD Screening and Testing in Breast Cancer, Breast Cancer Research and Treatment. pmc.ncbi.nlm.nih.gov} As guideline-led genetic assessment reaches more patients with breast, ovarian, pancreatic, and prostate cancers, testing volume can rise through changes in clinical pathways as well as disease incidence.^{[4]NCCN, Genetic/Familial High-Risk Assessment Guidelines. nccn.org}

Advancements in genomic technologies. NGS enables simultaneous interrogation of BRCA genes and additional homologous recombination repair genes, reducing the need to sequence separate single-analyte tests. Its commercial advantage is strongest in settings where tissue is limited or a patient may require several biomarker results to guide treatment. Broader panels also create a reporting challenge: laboratories must distinguish clinically actionable variants from findings of uncertain significance, making informatics and variant curation central to the product offering.

Rising expenditure for cancer treatment. Higher cancer-care spending increases the incentive to match expensive targeted therapies with patients most likely to benefit. OECD health-system data show that spending and access patterns vary markedly by country, which means reimbursement, laboratory capacity, and clinical guidance will determine whether testing adoption follows therapeutic availability. Biomarker testing becomes economically consequential when it is embedded in treatment pathways rather than ordered as a stand-alone diagnostic exercise.

Growing adoption of personalized medicine and precision therapy. Guideline recognition of genetic/familial risk assessment provides a durable institutional basis for testing, while therapy-linked companion diagnostics turn molecular results into prescribing requirements. The opportunity extends to liquid biopsy and circulating tumor DNA approaches where tissue access, disease progression, or repeat testing constrain conventional workflows. These approaches may expand testing access, but their adoption will depend on concordance evidence, regulatory acceptance, and payer coverage.

Key Restraints

High cost of PARP inhibitor biomarker test kits and assays. The relevant cost is not limited to the reagent price. Germline and tumor testing may require specimen logistics, sequencing infrastructure, confirmation, genetic counseling, bioinformatics, and physician interpretation. Published cost-effectiveness work demonstrates that the economic case depends on the tested population, testing strategy, and downstream treatment consequences. This makes low-resource settings and fragmented care pathways particularly difficult markets for broad-panel adoption.

Limited awareness and understanding of PARP inhibitor biomarkers. Testing gaps persist even in populations for whom guideline-supported assessment may be relevant. An analysis of HRD and BRCA testing patterns reported uneven testing coverage across populations. In practice, the barrier is often operational: a clinician must recognize the indication, order the appropriate test, obtain an adequate specimen, and receive a result early enough to influence the treatment decision. Education alone is insufficient if referral and laboratory workflows remain disconnected.

A bifurcated demand pattern is likely. Standardized BRCA workflows can scale through hospitals and high-volume laboratories, whereas HRD and broader HRR testing require more sophisticated interpretation and companion-diagnostic alignment. Suppliers that reduce pre-analytic complexity and produce decision-ready reports can address both the affordability challenge and the awareness gap more effectively than suppliers focused solely on analytical performance.

PARP Inhibitor Biomarkers Market Segment Analysis

By Product

Kits held 62.23% of 2023 revenue, according to GMI estimates. Their advantage is operational consistency: validated, packaged workflows can reduce variability across hospital and laboratory sites. Assays remain important where laboratories need to adapt a method to existing instrumentation, investigate specific variants, or support research protocols. The product choice therefore reflects the trade-off between standardized deployment and laboratory customization.

By Service

BRCA 1 & 2 testing accounted for 41.32% of service revenue in 2023, followed by HRD testing at 28.32% and HRR testing at 20.76%, according to GMI estimates. BRCA testing benefits from established hereditary-cancer pathways and therapy relevance. HRD testing expands the addressable testing population beyond single-gene alterations, particularly in ovarian cancer, but requires validated genomic-scarring or functional approaches and careful interpretation. Expert consensus in ovarian cancer continues to emphasize the importance of fit-for-purpose HRD testing in treatment planning.^{[5]Kuchenbaecker et al., HRD in Ovarian Cancer: Global Expert Consensus on Testing. pubmed.ncbi.nlm.nih.gov}

By Technology

NGS accounted for 51.26% of North American technology revenue in 2023, according to GMI estimates, compared with 27.52% for PCR. NGS is suited to multi-gene profiling and detection of diverse genomic variants, whereas PCR can offer rapid, targeted analysis when the clinical question is narrow. IHC and ISH retain complementary roles where protein expression or tissue morphology contributes to interpretation. No technology is universally substitutable: sample quality, gene-panel breadth, turnaround expectations, and reimbursement determine the appropriate platform.

By Application

Breast cancer led application demand with a 45.21% share in 2023, while ovarian cancer represented 40.98%, according to GMI estimates. Ovarian cancer's role is reinforced by established use of PARP inhibitors and the clinical need to assess HRD beyond BRCA status. Pancreatic cancer provides a smaller but clinically meaningful expansion route: meta-analytic evidence places germline BRCA2 prevalence at approximately 3.5%, while other series report BRCA alterations in roughly 5–8% of unselected pancreatic ductal adenocarcinoma cases. In prostate cancer, prospective data estimate an absolute prostate-cancer risk of 27% by age 75 among BRCA2 carriers, supporting continued attention to hereditary-risk and treatment-selection testing.

By End Use

Hospitals and clinics represented 42.79% of 2023 revenue, according to GMI estimates, because diagnosis, pathology review, treatment planning, and therapy administration converge in these settings. Diagnostic laboratories accounted for 28.34% and are positioned to concentrate specialized testing volumes, particularly where hospitals outsource complex NGS and interpretation. Academic and research institutes represented 18.34%, sustaining assay development and evidence generation, while other end users accounted for 10.53%. The competitive issue is not merely test location: it is whether each site can link a result to an oncology decision within the required clinical timeframe.

NGS is likely to remain the strategic technology anchor where panel breadth and future re-use of genomic data matter. PCR retains a defensible position for focused, time-sensitive testing. The more consequential segmentation shift is from test format to the service model around it: laboratories that combine genomic analysis, variant interpretation, and clinically legible reporting can capture value that reagent suppliers alone cannot.

PARP Inhibitor Biomarkers Market Regional Analysis

North America

North America was valued at USD 435.46 million in 2025 and is projected to reach USD 962.75 million by 2035, according to GMI estimates. The U.S. accounted for USD 392.50 million in 2025, while Canada is forecast to grow faster through 2035 at a 9.67% CAGR. The region combines a large oncology-testing base with evolving genetic-risk guidance. The American Cancer Society estimated approximately 310,720 new invasive breast cancer cases in the U.S. in 2024,^[6] and NCCN announced expanded genetic/familial high-risk assessment guidelines in November 2024. These conditions support adoption, although coverage and access remain uneven across care settings.

Europe

Europe was valued at USD 237.15 million in 2025 and is expected to reach USD 534.88 million by 2035, according to GMI estimates. The region's differentiator is its public genomics infrastructure. The European Commission's 1+Million Genomes initiative involves 24 Member States,^{[7]European Commission, 1+Million Genomes Initiative. digital-strategy.ec.europa.eu} and the European Genomic Data Infrastructure project was launched with EUR 40 million from the Digital Europe Programme. PCM4EU, an EU4Health-funded program running from January 2023 to June 2025, is applying NGS-based precision cancer medicine across participating systems. These initiatives can improve data interoperability and testing capability, but national reimbursement and laboratory implementation will determine commercial uptake.

Asia Pacific

Asia Pacific was valued at USD 264.45 million in 2025 and is projected to record an 8.73% CAGR through 2035, reaching USD 610.92 million, according to GMI estimates. Its growth profile reflects a broad range of cancer-care capacity and financing models. Analysis of the region indicates that high-income markets devote 5–9% of health spending to cancer, compared with 1–2% in middle-income markets. APEC's cancer-control work also identifies infrastructure, insurance, and collaboration as relevant access levers. Suppliers entering the region must therefore calibrate product complexity and service support to country-level laboratory maturity rather than treat Asia Pacific as a uniform testing market.

Latin America

Latin America was valued at USD 75.69 million in 2025 and is forecast to reach USD 164.02 million by 2035, according to GMI estimates. Brazil and Mexico are central to regional demand, but testing availability remains shaped by local laboratory networks and access to targeted therapy. Thermo Fisher Scientific and Pfizer partnered in 2023 to expand localized NGS-based cancer testing in more than 30 international markets, including Latin America. The partnership signals commercial efforts to broaden access; it does not establish a uniform public-investment or reimbursement environment across the region.

Middle East and Africa

The Middle East and Africa market was valued at USD 56.59 million in 2025 and is projected to reach USD 115.61 million by 2035, according to GMI estimates. Saudi Arabia is an important demand indicator: breast cancer accounted for 35.2% of female cancers in the country in 2023 and was the leading cancer site among women in GLOBOCAN 2022 data. A 2025 analysis reported an increase in the age-standardized breast-cancer incidence rate from 18.2 to 49.7 per 100,000 between 2007 and 2022. These data indicate a growing need for oncology diagnostics, although the pace of PARP biomarker adoption will depend on specialist capacity, laboratory access, and treatment availability.

Latin America and the Middle East and Africa present a more selective expansion opportunity. Partnerships that localize NGS testing can lower access barriers, but they do not eliminate the need for referral pathways, specialist interpretation, and therapy availability. Commercial success in these regions is likely to depend on phased deployment through capable reference laboratories and oncology centers rather than immediate broad-market penetration.

PARP Inhibitor Biomarkers Market Share & Competitive Landscape

According to GMI analysis, Illumina, Thermo Fisher Scientific, Foundation Medicine, QIAGEN, and Myriad Genetics collectively accounted for approximately 52% of market share. Competition is defined by control of different layers of the testing pathway: sequencing instruments and panels, sample preparation, bioinformatics, laboratory-developed or distributed tests, and companion-diagnostic evidence. A supplier's position strengthens when it can connect these layers without creating workflow friction for the ordering clinician or laboratory.

The authorized competitive set includes Agilent Technologies, Ambry Genetics, Amoy Diagnostics, BPS Bioscience, EntroGen, Foundation Medicine, Guardant Health, Illumina Inc., Invitae, Myriad Genetics, Pillar Biosciences, QIAGEN, and Thermo Fisher Scientific. Within this group, differentiation is increasingly visible in distributed HRD testing, liquid-biopsy capabilities, variant interpretation, and the availability of panels compatible with installed sequencing platforms.

Foundation Medicine's FDA-cleared companion-diagnostic position illustrates the importance of therapy-linked evidence: FoundationOne CDx and FoundationOne Liquid CDx were approved as companion diagnostics for Lynparza plus abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer,^{[8]Foundation Medicine, FDA Approval of FoundationOne CDx and FoundationOne Liquid CDx for Lynparza Plus Abiraterone in BRCA-Mutated mCRPC. foundationmedicine.com} and the associated FoundationOne CDx PMA supplement was approved in August 2024. QIAGEN and Myriad are pursuing a distributable NGS-based HRD testing model built around QIAseq xHYB technology and MyChoice CDx. This model can shift testing from a centralized service toward broader laboratory deployment, subject to validation and regulatory requirements.

Platform partnerships are another route to scale. Pillar Biosciences and Illumina partnered to make OncoReveal NGS panels, including BRCA1/2 plus CNV content, available globally, while Illumina expanded its TruSight Oncology portfolio in November 2024. Guardant Health's Guardant360 CDx received EU IVDR certification for tumor mutation profiling and companion-diagnostic indications in 2024. Invitae received FDA de novo authorization for a 47-gene hereditary cancer panel that includes BRCA1/2 in September 2023. These developments show that competitive advantage is being built through clinical validation, regulatory positioning, and access to distributed workflows, rather than through instrument performance alone.

Recent Industry Developments

• On September 3, 2024, Foundation Medicine announced FDA approval of FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for Lynparza plus abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer.
• On May 30, 2024, QIAGEN and Myriad Genetics announced development of a distributable NGS-based HRD test combining QIAseq xHYB technology with MyChoice CDx.
• On October 26, 2023, QIAGEN and Myriad Genetics announced a partnership to advance companion-diagnostic development for cancer.
• In 2024, Guardant Health received EU IVDR certification for Guardant360 CDx for tumor mutation profiling across solid cancers and companion-diagnostic indications.
• On September 29, 2023, the FDA granted de novo marketing authorization for Invitae's 47-gene hereditary cancer panel, which includes BRCA1 and BRCA2.
• On October 16, 2024, Pillar Biosciences expanded its commercial partnership with Illumina to support a broader OncoReveal portfolio, including a BRCA1/2+CNV panel, on the MiSeq i100 Series.
• In 2023, Thermo Fisher Scientific and Pfizer partnered to expand localized NGS-based cancer testing in more than 30 international markets across Latin America, the Middle East and Africa, and Asia.
• On January 18, 2024, Myriad Genetics announced its acquisition of the Precise Tumor Test, Precise Liquid Test, and a CLIA-certified laboratory from Intermountain Precision Genomics. The acquisition closed on February 1, 2024.